Cancer Research Targets Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Regala, R. P.
Right arrow Articles by Fields, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Regala, R. P.
Right arrow Articles by Fields, A. P.
[Cancer Research 65, 8905-8911, October 1, 2005]
© 2005 American Association for Cancer Research

Cell and Tumor Biology

Atypical Protein Kinase C{iota} Is an Oncogene in Human Non–Small Cell Lung Cancer

Roderick P. Regala1, Capella Weems1, Lee Jamieson1, Andras Khoor2, Eric S. Edell3, Christine M. Lohse4 and Alan P. Fields1

1 Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center; 2 Department of Pathology, Mayo Clinic, Jacksonville, Florida; and 3 Department of Medicine and 4 Division of Biostatistics, Mayo Clinic, Rochester, Minnesota

Requests for reprints: Alan P. Fields, Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Griffin Cancer Research Building, Room 312, 4500 San Pablo Road, Jacksonville, FL 32224. Phone: 904-953-6160; Fax: 904-953-0277; E-mail: fields.alan{at}mayo.edu.

Protein kinase C (PKC) isozymes have long been implicated in carcinogenesis. However, little is known about the functional significance of these enzymes in human cancer. We recently showed that the atypical PKC (aPKC) isozyme PKC{iota} is overexpressed in human non–small cell lung cancer (NSCLC) cells and that PKC{iota} plays a critical role in the transformed growth of the human lung adenocarcinoma A549 cell line in vitro and tumorigenicity in vivo. Here we provide compelling evidence that PKC{iota} is an oncogene in NSCLC based on the following criteria: (a) aPKC{iota} is overexpressed in the vast majority of primary NSCLC tumors; (b) tumor PKC{iota} expression levels predict poor survival in patients with NSCLC; (c) the PKC{iota} gene is frequently amplified in established NSCLC cell lines and primary NSCLC tumors; (d) gene amplification drives PKC{iota} expression in NSCLC cell lines and primary NSCLC tumors; and (e) disruption of PKC{iota} signaling with a dominant negative PKC{iota} allele blocks the transformed growth of human NSCLC cells harboring PKC{iota} gene amplification. Taken together, our data provide conclusive evidence that PKC{iota} is required for the transformed growth of NSCLC cells and that the PKC{iota} gene is a target for tumor-specific genetic alteration by amplification. Interestingly, PKC{iota} expression predicts poor survival in NSCLC patients independent of tumor stage. Therefore, PKC{iota} expression profiling may be useful in identifying early-stage NSCLC patients at elevated risk of relapse. Our functional data indicate that PKC{iota} is an attractive target for development of novel, mechanism-based therapeutics to treat NSCLC.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
R. P. Regala, R. K. Davis, A. Kunz, A. Khoor, M. Leitges, and A. P. Fields
Atypical Protein Kinase C{iota} Is Required for Bronchioalveolar Stem Cell Expansion and Lung Tumorigenesis
Cancer Res., October 1, 2009; 69(19): 7603 - 7611.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Ishiguro, K. Akimoto, Y. Nagashima, Y. Kojima, T. Sasaki, Y. Ishiguro-Imagawa, N. Nakaigawa, S. Ohno, Y. Kubota, and H. Uemura
aPKC{lambda}/{iota} promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6
PNAS, September 22, 2009; 106(38): 16369 - 16374.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Erdogan, E. W. Klee, E. A. Thompson, and A. P. Fields
Meta-analysis of Oncogenic Protein Kinase C{iota} Signaling in Lung Adenocarcinoma
Clin. Cancer Res., March 1, 2009; 15(5): 1527 - 1533.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
W. Guo, S. Wu, L. Wang, R.-y. Wang, X. Wei, J. Liu, and B. Fang
Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1)
Mol. Cancer Ther., February 1, 2009; 8(2): 441 - 448.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. R. Murray, J. Weems, U. Braun, M. Leitges, and A. P. Fields
Protein Kinase C {beta}II and PKC{iota}/{lambda}: Collaborating Partners in Colon Cancer Promotion and Progression
Cancer Res., January 15, 2009; 69(2): 656 - 662.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Guo, S. Wu, J. Liu, and B. Fang
Identification of a Small Molecule with Synthetic Lethality for K-Ras and Protein Kinase C Iota
Cancer Res., September 15, 2008; 68(18): 7403 - 7408.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
C. Chabu and C. Q. Doe
Dap160/intersectin binds and activates aPKC to regulate cell polarity and cell cycle progression
Development, August 15, 2008; 135(16): 2739 - 2746.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. P. Regala, E. A. Thompson, and A. P. Fields
Atypical Protein Kinase C{iota} Expression and Aurothiomalate Sensitivity in Human Lung Cancer Cells
Cancer Res., July 15, 2008; 68(14): 5888 - 5895.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
M. Lee and V. Vasioukhin
Cell polarity and cancer - cell and tissue polarity as a non-canonical tumor suppressor
J. Cell Sci., April 15, 2008; 121(8): 1141 - 1150.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Chen, C. Gould, R. Garza, T. Gao, R. Y. Hampton, and A. C. Newton
Amplitude Control of Protein Kinase C by RINCK, a Novel E3 Ubiquitin Ligase
J. Biol. Chem., November 16, 2007; 282(46): 33776 - 33787.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
M. Kim, A. Datta, P. Brakeman, W. Yu, and K. E. Mostov
Polarity proteins PAR6 and aPKC regulate cell death through GSK-3beta in 3D epithelial morphogenesis
J. Cell Sci., July 15, 2007; 120(14): 2309 - 2317.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K.-M. Bae, H. Wang, G. Jiang, M. G. Chen, L. Lu, and L. Xiao
Protein Kinase C{varepsilon} Is Overexpressed in Primary Human Non-Small Cell Lung Cancers and Functionally Required for Proliferation of Non-Small Cell Lung Cancer Cells in a p21/Cip1-Dependent Manner
Cancer Res., July 1, 2007; 67(13): 6053 - 6063.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Nanjundan, Y. Nakayama, K. W. Cheng, J. Lahad, J. Liu, K. Lu, W.-L. Kuo, K. Smith-McCune, D. Fishman, J. W. Gray, et al.
Amplification of MDS1/EVI1 and EVI1, Located in the 3q26.2 Amplicon, Is Associated with Favorable Patient Prognosis in Ovarian Cancer
Cancer Res., April 1, 2007; 67(7): 3074 - 3084.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Pu, M. L. Peach, S. H. Garfield, S. Wincovitch, V. E. Marquez, and P. M. Blumberg
Effects on Ligand Interaction and Membrane Translocation of the Positively Charged Arginine Residues Situated along the C1 Domain Binding Cleft in the Atypical Protein Kinase C Isoforms
J. Biol. Chem., November 3, 2006; 281(44): 33773 - 33788.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Sarkaria, P. O-charoenrat, S. G. Talbot, P. G. Reddy, I. Ngai, E. Maghami, K. N. Patel, B. Lee, Y. Yonekawa, M. Dudas, et al.
Squamous Cell Carcinoma Related Oncogene/DCUN1D1 Is Highly Conserved and Activated by Amplification in Squamous Cell Carcinomas
Cancer Res., October 1, 2006; 66(19): 9437 - 9444.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Erdogan, T. Lamark, M. Stallings-Mann, Lee Jamieson, M. Pellechia, E. A. Thompson, T. Johansen, and A. P. Fields
Aurothiomalate Inhibits Transformed Growth by Targeting the PB1 Domain of Protein Kinase C{iota}
J. Biol. Chem., September 22, 2006; 281(38): 28450 - 28459.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. A. Teicher
Protein kinase C as a therapeutic target.
Clin. Cancer Res., September 15, 2006; 12(18): 5336 - 5345.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Zhang, J. Huang, N. Yang, S. Liang, A. Barchetti, A. Giannakakis, M. G. Cadungog, A. O'Brien-Jenkins, M. Massobrio, K. F. Roby, et al.
Integrative Genomic Analysis of Protein Kinase C (PKC) Family Identifies PKC{iota} as a Biomarker and Potential Oncogene in Ovarian Carcinoma.
Cancer Res., May 1, 2006; 66(9): 4627 - 4635.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Stallings-Mann, L. Jamieson, R. P. Regala, C. Weems, N. R. Murray, and A. P. Fields
A Novel Small-Molecule Inhibitor of Protein Kinase C{iota} Blocks Transformed Growth of Non-Small-Cell Lung Cancer Cells
Cancer Res., February 1, 2006; 66(3): 1767 - 1774.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.